Skip to main content

Paul Ridker, MD

Paul Ridker, MD

Eugene Braunwald Professor

Harvard Medical School

Division of Cardiovascular Medicine

Director, Center for Cardiovascular Disease Prevention

Brigham and Women’s Hospital

Boston, MA

As a leading authority in LDL-C-mediated CV risk reduction, can you provide us with your perspective on the evidence for PCSK9 inhibitors as a foundational approach for managing a broad spectrum of patients with high risk coronary heart disease?

As a leading authority in LDL-C-mediated CV risk reduction, can you provide us with your perspective on the evidence for PCSK9 inhibitors as a foundational approach for managing a broad spectrum of patients with high risk coronary heart disease?

Paul Ridker, MD

As the Director of the Center for Cardiovascular Disease Prevention, what patient types on the risk landscape of ASCVD do you believe deserve special attention because they are likely to be eligible candidates for PCSK9-mediated LDL-C reduction?

As the Director of the Center for Cardiovascular Disease Prevention, what patient types on the risk landscape of ASCVD do you believe deserve special attention because they are likely to be eligible candidates for PCSK9-mediated LDL-C reduction?

Paul Ridker, MD

Based on ODYSSEY Outcomes, for which biological/metabolic risk markers do you feel that cardiologists and atherosclerosis specialists should strive to achieve LDL-C levels even more aggressive than those identified in the AHA Guidelines?

Based on ODYSSEY Outcomes, for which biological/metabolic risk markers do you feel that cardiologists and atherosclerosis specialists should strive to achieve LDL-C levels even more aggressive than those identified in the AHA Guidelines?

Paul Ridker, MD

You have identified the challenges of accessing PCSK9 inhibitors for patients whose CV risk is genetic vs. those whose clinical course is characterized by progressive vascular events. How do you approach each subset with respect to LDL-C management?

You have identified the challenges of accessing PCSK9 inhibitors for patients whose CV risk is genetic vs. those whose clinical course is characterized by progressive vascular events. How do you approach each subset with respect to LDL-C management?

Paul Ridker, MD

Professor Bhatt, you presented the pharmacoeconomic “in trial” analysis for alirocumab based on the ODYSSEY Outcomes Trial. Can you discuss the clinical implications of your analysis, and how reduced costs for alirocumab will affect IC practice?

Professor Bhatt, you presented the pharmacoeconomic “in trial” analysis for alirocumab based on the ODYSSEY Outcomes Trial. Can you discuss the clinical implications of your analysis, and how reduced costs for alirocumab will affect IC practice?

Deepak Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

Paul Ridker, MD

From the view of an interventional cardiologist and a lipid medicine/atherosclerosis specialist, can you discuss what LDL-C thresholds vs. clinical burden/clinical history thresholds are important for patient selection for PCSK9-based risk reduction?

From the view of an interventional cardiologist and a lipid medicine/atherosclerosis specialist, can you discuss what LDL-C thresholds vs. clinical burden/clinical history thresholds are important for patient selection for PCSK9-based risk reduction?

Deepak Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

Paul Ridker, MD

IC and lipid specialists are challenged to maximize CV risk reduction in high-risk populations. How should they approach the 70 mg/dL LDL-C target identified in the AHA Guidelines, and when is the 30 mg/dL – 70 mg/dL even more desirable?

IC and lipid specialists are challenged to maximize CV risk reduction in high-risk populations. How should they approach the 70 mg/dL LDL-C target identified in the AHA Guidelines, and when is the 30 mg/dL – 70 mg/dL even more desirable?

Deepak Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

Paul Ridker, MD

How do you identify “progressing patients” with high CV risk in whom PCSK9 therapy represents a game-changing strategy?

How do you identify “progressing patients” with high CV risk in whom PCSK9 therapy represents a game-changing strategy?

Deepak Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

Paul Ridker, MD

What other markers, besides LDL-C levels, do you believe we should consider to refine CV risk stratification?

What other markers, besides LDL-C levels, do you believe we should consider to refine CV risk stratification?

Deepak Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

Paul Ridker, MD